Boston, MA 02/13/2014 (wallstreetpr) – Pfizer Inc. (NYSE:PFE) the American biotechnology company which also has a presence the pharmaceutical industry has a broad spectrum of multiple drugs – Viagra, Lipitor, Celebrex as well as Zithromax. The company despite its high-profile growth has since dropped top executive Amy Shulman, who headed the healthcare segment on a global platform. Following her exit, despite a brilliant career within Pfizer Inc. (NYSE:PFE), investor community are cautious about the way forward for Pfizer.
Separately, the company has also entered into an agreement with Merck to test the drug MK-3475 immunotherapy cancer treatment. Besides, Merck & Co., Inc. (NYSE:MRK) has also entered into similar agreements two other companies as well, and these two well evaluate MK-3475 along same parameters.
Meanwhile, Cereplast Inc (OTCMKTS:CERP), stands to benefit from the transition of most European countries to higher microns plastic. This is especially applicable in the case of plastic carry bags. Cereplast, Inc. (OTCQB:CERP), is one of the pioneering companies which offer innovative technologies, which is largely proprietary in nature, to convert virgin plastic to biodegradable standards. The use of bio-substitutes is the technology innovation, which allows Cerplast to offer plastic-domain products scaling industries. All these products by this innovative biotechnology company are biodegradable.
The Western Union Company (NYSE:WU), the US-based money transfer and payment services provider has announced its fourth quarter results. The main line of revenues for the company has been the customer to customer transactions, which grew by 9%. The proactive pricing led to higher demand, it appears in retrospective. However, these did cut into the operating margins for this money transfer conglomerate. In the past year, the prices supporting exchanges has varied dropping as low as 16.8% in comparison to the 20.1% than, over a year ago. In the meanwhile, The Western Union Company (NYSE:WU) has also introduced a new repurchase plan. The guidance for FY14 EPS is $1.40 and $1.50 which is in-line with consensus of $1.46.
